Talus Bio GTM brain

Talus Bio develops structure-free drug discovery models and live-cell proteomics for biotech and pharmaceutical discovery teams.

category

AI and functional proteomics drug discovery

market profile

  • text: Drug discovery teams need ways to investigate disordered regulatory proteins that lack conventional binding pockets.
  • text: Talus combines its own therapeutic development with research partnerships and model access.

personas

  • title: VP drug discovery or head of biology
    pains:
    • Disease-relevant transcription factors resist conventional structure-based screening
    • Promising computational hits require validation in native cells
  • title: Computational chemistry or AI discovery lead
    pains:
    • Known structures and binding pockets are unavailable for flexible targets
    • Proteome-wide selectivity is difficult to assess early
  • title: Pharma business development lead
    pains:
    • Needs differentiated external platforms and clear collaboration economics
    • Must establish a credible path to validated chemical matter

icp

  • text: Biopharma companies with small-molecule discovery programs targeting transcription factors, protein interactions or disordered proteins.
  • text: Drug discovery groups with computational screening and cellular validation capabilities seeking new target classes.

message pillars

  • text: Reach targets without an existing structure.
  • text: Screen at scale and assess selectivity.
  • text: Measure compound effects in native cellular context.

objections

  • objection: Are model predictions experimentally proven?
    response: Predictions require experimental validation; use a prospective target-specific pilot with agreed hit and selectivity metrics.
  • objection: How would a collaboration handle IP and risk?
    response: Discuss target-specific rights and economics; Talus describes a cost and profit sharing model with PRISM, not a universal template.

competitors

  • name: Foghorn Therapeutics
    why: Develops therapies targeting gene regulation and transcription factor interactions.
  • name: DarwinHealth
    why: Applies computational biology to transcription factor driven cancer drug discovery.

influencers

  • name: Alex Federation
    url: https://www.ycombinator.com/companies/talus-bio
    why: CEO and co-founder discussing transcription factor discovery.
  • name: Lindsay Pino
    url: https://www.ycombinator.com/companies/talus-bio
    why: Co-founder and technology leader.

keywords

  • transcription factor drug discovery
  • structure free drug discovery
  • functional proteomics screening
  • disordered protein drug targets
  • small molecule selectivity profiling
  • regulome profiling

voice

  • scientifically precise
  • ambitious but validation aware
  • mechanism focused

signals

  • text: A pharma discovery team announces a transcription factor or intrinsically disordered target program.
  • text: A biotech seeks a platform partner for small-molecule discovery on difficult protein interactions.

pricing

model: unknown

motion

hybrid

channels

  • scientific publications
  • industry conferences
  • partnerships
  • LinkedIn

confidence

high

Founders

  • name: Alex Federation
    title: Founder
    role: Founder
    bio: I'm the co-founder of Talus Bio. Prior to Talus, I trained with Jay Bradner at Harvard in medicinal chemistry, drug screening, and drug development for gene regulators. After that, I moved to Seattle to continue my training in epigenomics and proteomics, and these were all combined to develop the Talus gene regulator platform.
  • name: Lindsay Pino
    title: Founder
    role: Founder
    bio: I'm Talus Bio's CTO, where my focus is on developing techniques for quantitative proteomics and in particular the challenges associated with scaling-up quantitative proteomics experiments. I’ve trained at the Broad Institute, the University of Washington, and most recently the University of Pennsylvania.

Back to YC companies